Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

>Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to Phase 1/2 clinical data of MDX-060 in lymphoma may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Through rare discovery of new physics and ... is enabling World Scientists to actually see, watch, and ... the full nature (position, shape, size, number) of molecules, ... Co-Founder of the Yancy Corporation, says, "Our rare discoveries ... come once in a lifetime, if at all. Our ...
(Date:6/2/2015)... GenoCAD , a platform leveraging ... expression, announced the formation of its new board of ... with a broad range of experience in the biotechnology, ... includes: , Jimmy Roussel, Entrepreneur in Residence at The ... in technology and marketing. He has served in operations ...
(Date:6/1/2015)... 2015 Research and ... addition of the "Oxidative Stress Assay ... Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769) , The global oxidative ...
(Date:6/1/2015)... , June 1, 2015 GenomeDx ... genomic analysis platform, successfully classified various subtypes ... expression of certain biomarkers, including one type ... this unique genomic signature has potential as ... neoadjuvant chemotherapy in patients with muscle-invasive bladder ...
Breaking Biology Technology:Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4
... Nov. 21 Gen-Probe,s (Nasdaq: GPRO ... new molecular tool to more,accurately detect high-risk human ... or precancerous lesions, according to nine,oral presentations and ... Gen-Probe researchers at the international conference of the,European ...
... of NC,s biotechnology sector is $45.8 billion, 180,007 jobs , ... Nov. 20 North Carolina has invested more than $1 ... years, and the annual economic impact exceeds $45 billion, according ... , , Norris Tolson, president ...
... Discovery Channel, will showcase the cutting edge technology and on-site laboratories ... ... (Vocus) November 20, 2008 -- Lake Erie Biofuels, LLC , ... biodiesel in the Northeastern United States and will soon be introduced ...
Cached Biology Technology:Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 2Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 3Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 5North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 2North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 3North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 4North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 5Discovery Channel to Feature Lake Erie Biofuels, LLC 2Discovery Channel to Feature Lake Erie Biofuels, LLC 3
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... European Experts in the field of life in extreme ... Antarctic Survey offices in Cambridge (UK) to officially kick ... on life in Extreme Environments). , Life in Extreme ... Europe has considerable expertise but a relatively fragmented research ...
... of the oxygen we breathe today is being produced ... scientists heard today (Wednesday 2 April 2008) at the ... week at the Edinburgh International Conference Centre. About ... photosynthesising creatures called phytoplankton in the major oceans. These ...
... HARBOR, N.Y. (Tuesday, April 1, 2008) Identifying ... in the mouse used to be a monumental task. ... making it effective for even the smallest laboratories. ... ( www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for screening ...
Cached Biology News:Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... RNA stain is used to stain and ... agarose gels and does not interfere with ... nm transilluminator, the stain emits a red-orange ... film or with a CCD camera-based gel ...
... mitochondrial transmembrane potential is one ... that occur following induction of ... Kit utilizes a lipophilic cation, ... mitochondrial activity marker. MitoLight partitions ...
Biology Products: